Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocon Limited ( (IN:BIOCON) ) has issued an announcement.
Biocon Limited’s subsidiary, Biocon Pharma Limited, has received approval from the U.S. FDA for its ANDA for Tofacitinib Extended-Release Tablets, with final approval for the 11mg strength and tentative approval for the 22mg strength. This approval enhances Biocon’s portfolio in complex drug products, potentially strengthening its market position and offering new treatment options for conditions such as Rheumatoid Arthritis and Ulcerative Colitis.
More about Biocon Limited
Biocon Limited is a prominent player in the biotechnology industry, primarily focusing on the development and production of pharmaceutical products. The company is known for its vertically integrated, complex drug products and has a significant market presence in the field of biopharmaceuticals.
Average Trading Volume: 113,274
Technical Sentiment Signal: Buy
Current Market Cap: 548.4B INR
For an in-depth examination of BIOCON stock, go to TipRanks’ Overview page.